O	0	14	Cardiovascular
O	15	19	risk
O	20	27	profile
O	28	30	of
O	31	39	patients
O	40	44	with
O	45	49	HER2
O	49	50	/
O	50	53	neu
O	53	54	-
O	54	62	positive
O	63	69	breast
O	70	76	cancer
O	77	84	treated
O	85	89	with
B-intervention	90	103	anthracycline
I-intervention	103	104	-
I-intervention	104	110	taxane
I-intervention	110	111	-
I-intervention	111	121	containing
I-intervention	122	130	adjuvant
I-intervention	131	143	chemotherapy
I-intervention	144	147	and
I-intervention	147	148	/
I-intervention	148	150	or
I-intervention	151	162	trastuzumab
O	162	163	.

O	164	166	To
O	167	175	evaluate
O	176	179	the
O	180	194	cardiovascular
O	195	199	risk
O	200	207	profile
O	208	210	of
O	211	212	a
O	213	219	subset
O	220	222	of
O	223	231	patients
O	232	236	with
O	237	242	early
O	242	243	-
O	243	248	stage
O	249	255	breast
O	256	262	cancer
O	263	270	treated
O	271	275	with
O	276	284	adjuvant
O	285	291	taxane
O	291	292	-
O	292	305	anthracycline
O	305	306	-
O	306	316	containing
O	317	329	chemotherapy
O	330	333	and
O	333	334	/
O	334	336	or
O	337	348	trastuzumab
O	349	350	(
O	350	359	Herceptin
O	359	360	)
O	360	361	.

B-intervention-participants	362	368	Twenty
I-intervention-participants	368	369	-
I-intervention-participants	369	372	six
B-eligibility	373	381	patients
I-eligibility	382	386	with
I-eligibility	387	393	breast
I-eligibility	394	400	cancer
O	401	402	(
O	402	406	mean
O	406	407	,
O	408	410	20
O	411	417	months
O	418	434	postchemotherapy
O	434	435	)
O	436	439	and
B-control-participants	440	442	10
B-control	443	450	healthy
O	451	454	age
O	454	455	-
O	455	462	matched
O	463	468	women
O	469	473	were
O	474	481	studied
O	481	482	.

O	483	485	We
O	486	494	measured
O	495	497	14
O	498	507	metabolic
O	508	511	and
O	512	520	vascular
O	521	532	established
O	533	547	cardiovascular
O	548	555	disease
O	556	557	(
O	557	560	CVD
O	560	561	)
O	562	566	risk
O	567	574	factors
O	574	575	,
O	576	580	body
O	581	585	mass
O	586	591	index
O	591	592	,
O	593	610	cardiorespiratory
O	611	618	fitness
O	618	619	,
O	620	623	and
O	624	628	left
O	629	640	ventricular
O	641	649	systolic
O	650	658	function
O	658	659	.

O	660	663	All
O	664	675	assessments
O	676	680	were
O	681	685	done
O	686	692	within
O	693	694	a
O	695	697	14
O	697	698	-
O	698	701	day
O	702	708	period
O	708	709	.

O	710	717	Cardiac
O	718	731	abnormalities
O	732	736	were
O	737	746	suggested
O	747	749	by
O	750	754	left
O	755	766	ventricular
O	767	775	ejection
O	776	784	fraction
O	785	786	(
O	786	790	LVEF
O	790	791	)
O	792	793	<
O	793	795	50
O	795	796	%
O	797	799	in
O	800	801	8
O	801	802	%
O	803	805	of
O	806	814	patients
O	814	815	,
O	816	820	LVEF
O	821	829	remained
O	830	831	>
O	831	833	10
O	833	834	%
O	835	840	below
O	841	853	pretreatment
O	854	860	values
O	861	863	in
O	864	866	38
O	866	867	%
O	867	868	,
O	869	876	whereas
O	877	879	50
O	879	880	%
O	881	890	presented
O	891	895	with
O	896	903	resting
O	904	909	sinus
O	910	921	tachycardia
O	921	922	.

B-outcome	923	928	Brain
I-outcome	929	940	natriuretic
I-outcome	941	948	peptide
O	949	952	was
O	953	966	significantly
O	967	975	elevated
O	976	978	in
O	979	981	40
O	981	982	%
O	983	985	of
O	986	994	patients
O	995	998	and
O	999	1002	was
O	1003	1013	correlated
O	1014	1018	with
O	1019	1023	LVEF
O	1024	1025	(
O	1025	1026	r
O	1027	1028	=
O	1029	1030	-
O	1030	1031	0
O	1031	1032	.
O	1032	1034	72
O	1034	1035	,
O	1036	1037	P
O	1038	1039	=
O	1039	1041	or
O	1041	1042	<
O	1043	1044	0
O	1044	1045	.
O	1045	1048	001
O	1048	1049	)
O	1049	1050	.

O	1051	1054	For
O	1055	1058	the
O	1059	1067	majority
O	1068	1070	of
O	1071	1074	CVD
O	1075	1079	risk
O	1080	1087	factors
O	1087	1088	,
O	1089	1096	similar
O	1097	1108	proportions
O	1109	1111	of
O	1112	1120	patients
O	1121	1124	and
O	1125	1133	controls
O	1134	1135	(
O	1135	1137	35
O	1137	1138	-
O	1138	1140	60
O	1140	1141	%
O	1141	1142	)
O	1143	1147	were
O	1148	1158	classified
O	1159	1161	as
O	1162	1163	"
O	1163	1174	undesirable
O	1174	1175	.
O	1175	1176	"
O	1177	1178	A
O	1179	1192	significantly
O	1193	1199	higher
O	1200	1210	proportion
O	1211	1213	of
O	1214	1222	patients
O	1223	1227	were
O	1228	1238	classified
O	1239	1243	with
B-outcome	1244	1247	low
I-outcome	1248	1265	cardiorespiratory
I-outcome	1266	1273	fitness
O	1274	1275	(
B-iv-bin-percent	1275	1277	46
I-iv-bin-percent	1277	1278	%
O	1279	1285	versus
B-cv-bin-percent	1286	1287	0
I-cv-bin-percent	1287	1288	%
O	1288	1289	,
O	1290	1291	P
O	1292	1293	<
O	1294	1295	0
O	1295	1296	.
O	1296	1298	01
O	1298	1299	)
O	1299	1300	,
O	1301	1306	being
B-outcome	1307	1317	overweight
I-outcome	1317	1318	/
I-outcome	1318	1323	obese
O	1324	1325	(
B-iv-bin-percent	1325	1327	72
I-iv-bin-percent	1327	1328	%
O	1329	1335	versus
B-cv-bin-percent	1336	1338	50
I-cv-bin-percent	1338	1339	%
O	1339	1340	,
O	1341	1342	P
O	1343	1344	<
O	1345	1346	0
O	1346	1347	.
O	1347	1349	05
O	1349	1350	)
O	1350	1351	,
O	1352	1355	and
O	1356	1362	having
B-outcome	1363	1370	resting
I-outcome	1371	1376	sinus
I-outcome	1377	1388	tachycardia
O	1389	1390	(
B-iv-bin-percent	1390	1392	50
I-iv-bin-percent	1392	1393	%
O	1394	1400	versus
B-cv-bin-percent	1401	1402	0
I-cv-bin-percent	1402	1403	%
O	1403	1404	,
O	1405	1406	P
O	1407	1408	<
O	1409	1410	0
O	1410	1411	.
O	1411	1413	01
O	1413	1414	)
O	1415	1423	compared
O	1424	1428	with
O	1429	1437	controls
O	1437	1438	.

B-outcome	1439	1456	Cardiorespiratory
I-outcome	1457	1464	fitness
O	1465	1468	and
B-outcome	1469	1473	body
I-outcome	1474	1478	mass
I-outcome	1479	1484	index
O	1485	1489	were
O	1490	1500	correlated
O	1501	1505	with
O	1506	1509	CVD
O	1510	1514	risk
O	1515	1522	factors
O	1523	1524	(
O	1524	1525	r
O	1526	1527	=
O	1528	1529	-
O	1529	1530	0
O	1530	1531	.
O	1531	1533	64
O	1534	1536	to
O	1537	1538	0
O	1538	1539	.
O	1539	1541	63
O	1541	1542	,
O	1543	1544	P
O	1545	1546	<
O	1547	1548	0
O	1548	1549	.
O	1549	1551	05
O	1551	1552	;
O	1553	1554	r
O	1555	1556	=
O	1557	1558	-
O	1558	1559	0
O	1559	1560	.
O	1560	1562	63
O	1563	1565	to
O	1566	1567	0
O	1567	1568	.
O	1568	1570	67
O	1570	1571	,
O	1572	1573	P
O	1574	1575	<
O	1576	1577	0
O	1577	1578	.
O	1578	1580	05
O	1580	1581	,
O	1582	1594	respectively
O	1594	1595	)
O	1595	1596	.

O	1597	1608	Exploratory
O	1609	1617	analyses
O	1618	1626	revealed
O	1627	1634	several
O	1635	1646	differences
O	1647	1654	between
O	1655	1658	CVD
O	1659	1663	risk
O	1664	1671	factors
O	1672	1677	based
O	1678	1680	on
O	1681	1693	chemotherapy
O	1694	1701	regimen
O	1701	1702	.

O	1703	1709	Breast
O	1710	1716	cancer
O	1717	1726	survivors
O	1727	1734	treated
O	1735	1739	with
O	1740	1748	adjuvant
O	1749	1761	chemotherapy
O	1762	1765	are
O	1766	1768	at
O	1769	1770	a
O	1771	1777	higher
O	1778	1782	risk
O	1783	1785	of
O	1786	1796	developing
O	1797	1801	late
O	1801	1802	-
O	1802	1811	occurring
O	1812	1815	CVD
O	1816	1820	than
O	1821	1824	age
O	1824	1825	-
O	1825	1832	matched
O	1833	1841	controls
O	1842	1845	due
O	1846	1848	to
O	1849	1855	direct
O	1856	1859	and
O	1860	1868	indirect
O	1869	1878	treatment
O	1878	1879	-
O	1879	1886	related
O	1887	1895	toxicity
O	1895	1896	.
